GMED icon

Globus Medical

69.39 USD
-1.62
2.28%
At close Apr 21, 4:00 PM EDT
1 day
-2.28%
5 days
-6.66%
1 month
-5.71%
3 months
-24.91%
6 months
-5.58%
Year to date
-15.20%
1 year
35.40%
5 years
54.61%
10 years
174.81%
 

About: Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States. It also has its presence internationally.

Employees: 5,300

0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

140% more first-time investments, than exits

New positions opened: 103 | Existing positions closed: 43

110% more call options, than puts

Call options by funds: $24.5M | Put options by funds: $11.7M

18% more capital invested

Capital invested by funds: $7.6B [Q3] → $9B (+$1.39B) [Q4]

11% more repeat investments, than reductions

Existing positions increased: 167 | Existing positions reduced: 150

11% more funds holding

Funds holding: 443 [Q3] → 492 (+49) [Q4]

6% more funds holding in top 10

Funds holding in top 10: 18 [Q3] → 19 (+1) [Q4]

1.56% more ownership

Funds ownership: 94.07% [Q3] → 95.63% (+1.56%) [Q4]

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$80
15%
upside
Avg. target
$93
33%
upside
High target
$103
48%
upside

4 analyst ratings

positive
75%
neutral
25%
negative
0%
Truist Securities
Richard Newitter
46% 1-year accuracy
22 / 48 met price target
15%upside
$80
Hold
Maintained
11 Apr 2025
Barclays
Matt Miksic
44% 1-year accuracy
18 / 41 met price target
48%upside
$103
Overweight
Maintained
24 Feb 2025
Stifel
Mathew Blackman
24% 1-year accuracy
4 / 17 met price target
35%upside
$94
Buy
Maintained
21 Feb 2025
Wells Fargo
Vik Chopra
27% 1-year accuracy
3 / 11 met price target
34%upside
$93
Overweight
Maintained
21 Feb 2025

Financial journalist opinion

Based on 5 articles about GMED published over the past 30 days

Positive
Zacks Investment Research
3 days ago
Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report?
Globus Medical (GMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Will Globus Medical (GMED) Beat Estimates Again in Its Next Earnings Report?
Neutral
GlobeNewsWire
4 days ago
Globus Medical Schedules First Quarter Earnings Release and Conference Call
AUDUBON, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the first quarter ended March 31, 2025 after the market close on Thursday, May 8, 2025. A copy of the release will be available on the Globus Medical website at www.investors.globusmedical.com.
Globus Medical Schedules First Quarter Earnings Release and Conference Call
Positive
Zacks Investment Research
1 week ago
International Growth Drives GMED Stock Amid Fierce Competition
Globus Medical is gearing up for a series of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
International Growth Drives GMED Stock Amid Fierce Competition
Positive
Zacks Investment Research
2 weeks ago
GMED Stock May Benefit Following the Acquisition of Nevro
Globus Medical acquires Nevro Corp. to expand its presence in the $2.50 billion musculoskeletal market.
GMED Stock May Benefit Following the Acquisition of Nevro
Neutral
GlobeNewsWire
2 weeks ago
Globus Medical completes acquisition of Nevro Corp.
AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain.
Globus Medical completes acquisition of Nevro Corp.
Neutral
Business Wire
1 month ago
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Nevro Corp. (NYSE: NVRO) to Globus Medical, Inc. (NYSE: GMED). Under the terms of the proposed transaction, shareholders of Nevro will receive $5.85 in cash for each share of Nevro that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or w.
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO
Positive
Zacks Investment Research
1 month ago
GMED Stock Jumps 41.8% in a Year: What's Behind the Rally?
Globus Medical's robust musculoskeletal offerings and synergies from the NuVasive merger are fueling its stock gains.
GMED Stock Jumps 41.8% in a Year: What's Behind the Rally?
Positive
Zacks Investment Research
1 month ago
Should You Hold Globus Medical Stock in Your Portfolio Now?
GMED stays on investors' radar due to its high NuVasive-merger synergies and solid Musculoskeletal prospects.
Should You Hold Globus Medical Stock in Your Portfolio Now?
Positive
Zacks Investment Research
1 month ago
New Product Launches Benefit GMED Stock Amid Macro Issues
Globus Medical currently awaits a strong cadence of product launches throughout the Musculoskeletal portfolio in the coming months of 2025.
New Product Launches Benefit GMED Stock Amid Macro Issues
Positive
Zacks Investment Research
1 month ago
Globus Medical Expands Anterior Spine Portfolio With Two New Offerings
GMED announces the commercial launch of COHERE ALIF Spacer and Modulus ALIF Blades.
Globus Medical Expands Anterior Spine Portfolio With Two New Offerings
Charts implemented using Lightweight Charts™